SCHEMBL3389130

SCHEMBL3389130

Cc1cc(C)nc(-c2ccc(C)nc2C#N)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP8 P40818 1/20 0.38
USP7 Q93009 1/20 0.38
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
ALDH1A1 P00352 6/20 0.35
KDM4E B2RXH2 4/20 0.35
HPGD P15428 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ABCG2 Q9UNQ0 1/20 0.35
RXFP1 Q9HBX9 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
USP2 O75604 1/20 0.34
MAPT P10636 1/20 0.34
HTT P42858 1/20 0.34
PPARG P37231 1/20 0.33
STAT3 P40763 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
NR2E3 Q9Y5X4 1/20 0.33
NCOR2 Q9Y618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL262916 0.80 CLK4 (0.36) USP8USP7ALDH1A1KDM4EHPGD
SCHEMBL30775027 0.79 USP8 (0.36) USP8USP7ALDH1A1KDM4ESMN1; SMN2
SCHEMBL3387027 0.79 USP8 (0.36) USP8USP7ALDH1A1KDM4ESMN1; SMN2
SCHEMBL3387193 0.76 USP8 (0.35) USP8USP7ALDH1A1KDM4EHPGD
SCHEMBL2474490 0.73 CCR1 (0.52) USP8
SCHEMBL30775065 0.73 ALDH1A1 (0.39) MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL3388543 0.73 ALDH1A1 (0.39) MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL16277505 0.71 ALOX15 (0.44) USP8USP7MEN1KMT2AALDH1A1
SCHEMBL929272 0.71 KMT2A (0.42) USP8MEN1KMT2AALDH1A1KDM4E
SCHEMBL17151367 0.70 ALDH1A1 (0.51) USP8USP7MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010063663-A1 N-{[(IR,4S,6R-3-(2-PYRIDINYLCARBONYL)-3-AZABICYCLO [4.1.0]HEPT-4-YL] METHYL}-2-HETEROARYLAMINE DERIVATIVES AND USES THEREOF GLAXO GROUP LIMITED (GB) 2010-06-10 WO disclosed
US-20100144760-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2010-06-10 US disclosed
US-20100144760-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2010-06-10 US disclosed
US-20100144760-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144760-A1 NOVEL COMPOUNDS HTR3B, HTR1B, HTR2B USP8 4226/4885USP7 4375/4885MEN1 1353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.